|Articles|September 1, 2010

Oncology NEWS International

Oncology NEWS International Vol 19 No 9
Volume 19
Issue 9

Research chair named after Dr. Salem

St. Luke’s Episcopal Hospital has established the Philip A. Salem, MD, Chair in Cancer Research.

PHILIP A. SALEM, MD

St. Luke's Episcopal Hospital has established the Philip A. Salem, MD, Chair in Cancer Research. This is the first chair in cancer research established at the Houston-based hospital which is part of the Texas Medical Center.

Dr. Salem is the director of the cancer research program at St. Luke's. His groundbreaking work in chemoprevention, including the link between chronic gastrointestinal infections and the risk of cancer, has led to research focusing on isolating and treating precancerous infections.

Articles in this issue

over 15 years ago

Article

PSA test drives diagnosis within families

over 15 years ago

Article

New RT journal calls for papers

over 15 years ago

Article

Oral Bisphosphonates Not Linked to Esophageal Cancer Risk

over 15 years ago

Article

Partnering of chemotherapy and radiation yields great response rates in H&N ca, but has not improved survival

over 15 years ago

Article

Should radiation therapy plus hormone therapy be the new standard of care for locally advanced prostate cancer?

over 15 years ago

Article

Zoledronic acid plus standard therapy offers anticancer effect in multiple myeloma

over 15 years ago

Article

Ipilimumab put on fast track by FDA

over 15 years ago

Article

Who's News

over 15 years ago

Article

ASTRO releases breast RT guide

over 15 years ago

Article

Breast Cancer Specialists Brace for FDA Word on Avastin

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!

Research chair named after Dr. Salem

Articles in this issue

Newsletter

Related Content

Pelareorep Exhibits Activity in Second-Line KRAS-Mutated Metastatic CRC

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

Response Rates Show Promise in Phase 1 Trial Involving ASCT in Metastatic PDAC

Porustobart/Tislelizumab Elicits Responses in MSS Metastatic Colorectal Cancer

Nivolumab/Ipilimumab Maintain PFS Benefit vs Nivolumab Monotherapy in MSI-H/dMMR CRC

Latest CME

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | Indiana

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Missouri

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | New Mexico

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | North Carolina

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | West Virginia

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Tennessee

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Washington

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | South Carolina

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Texas

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | Nevada

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Arkansas

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Kentucky

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | New York

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | Iowa

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Minnesota

11th Annual School of Gastrointestinal Oncology® (SOGO®)

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Breaking Down the Rationale for Targeting TROP2 in TNBC

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Establishing the Rationale for ADC and ICI Combinations in TNBC

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Optimizing Treatment for Biliary Tract Cancers

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Cross-Disease Integration of Immunotherapy Innovations

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Radioligand Therapy 101: The Science Behind the Strategy

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

21st Annual New York Lung Cancers Symposium®

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

9th Annual School of Nursing Oncology™

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Biomarker Testing in HER2+ GEA: Diagnosis and Treatment Implications

(Pharmacist Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Evolving Strategies and Emerging Agents in PTCL: Subtypes, Mutations, and Modern Therapies

Collaborating Across the Continuum®: Identifying and Treating Epithelioid Sarcoma

Epithelioid Sarcoma: Applying Clinical Updates to Real Patient Cases

Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care

Cases and Conversations: Real-World Insights in Advancing Management of Myelofibrosis and Polycythemia Vera – How the Experts Apply the Latest Developments in Care

Mastering Epithelioid Sarcoma: Enhancing Diagnostic Precision and Tailoring Treatment Strategies

Clinical Showcase™: Selecting the Best Next Steps for a Patient with Epithelioid Sarcoma

Inaugural Brain & Spine Metastases Conference: Evolving Practice and Emerging Therapies

2nd Annual Hawaii Cancer Conference

Medical Crossfire®: Bridging Evidence to Practice in AML…Updates on FLT3, IDH1/2, Maintenance, Combos, and Clinical Trials

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers

19th Annual New York GU Cancers Congress™

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Addressing Unmet Needs in HER2+ Metastatic BTC

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment